Collective2 is the established US strategy marketplace: strategy authors list systems, subscribers autotrade them across supported brokers. Sonar Sciences is an evidence-first platform where every result is computed by the platform itself. Here is the honest comparison for a strategy author weighing the two.
Collective2 has operated for two decades, supports stocks, futures, options, and forex, and connects subscriber autotrading across dozens of brokers. Its audience exists today: publishing there puts a strategy in front of an established subscriber base immediately, and long-tenured strategies carry visible multi-year track records. For US-market strategies wanting immediate distribution, it is the incumbent for a reason.
| Dimension | Collective2 | Sonar Sciences |
|---|---|---|
| Cost to list | Listing fee, published at $120 per 6 months | Nothing up front; the Studio is free |
| Platform share | 30 to 50% of subscription revenue, per its published pages | Nothing to list; the execution fee applies to your own winning trades only |
| Revenue model | Flat subscriptions, earned win or lose | No revenue share: the platform charges on your own winning trades, not anybody else's |
| Evidence standard | On-platform track record; no validation gate before listing | Platform-computed results on four years of data, out-of-sample gate and a ten-day live forward round before you commit money |
| History integrity | Record accrues while listed | Versioned: results permanently attached to the version that produced them |
| Market focus | US equities, futures, options, forex | Gold, FX majors, indices, oil; EA and rule-based workflows |
| Maturity | Established audience today | Newer platform; audience building |
Figures are Collective2's published terms as of July 2026; verify current terms directly before listing.
On Collective2, a strategy builds its record by trading on-platform, which is meaningful but starts at zero credibility, and subscription economics mean fees accrue whether subscribers win or lose, a structure its own community forums debate. On Sonar Sciences, a strategy arrives with computed evidence: four years of cost-inclusive backtest, parameter stability, and an out-of-sample verdict, all produced by the platform, and its live economics only pay anyone when trades win. One model sells tenure; the other sells validation.
Choose Collective2 if you trade US equities or futures, want an existing subscriber base this quarter, and are prepared to pay listing fees while building an on-platform record. Choose Sonar Sciences if your work is rule-based or EA-driven on FX, gold, indices, or oil, you want the verdict now rather than after months of building a record in public, and you prefer economics where the platform earns only when your own trades win. Running both is legitimate: tenure where tenure lives, validation where validation lives.
Not today, and the reason is worth being plain about: Collective2 is a marketplace where authors take subscribers, and Sonar Sciences does not offer that. What it replaces is the evidence half. Nothing on Sonar is reported without the platform's own four-year backtest and a ten-day live forward round, there are no listing fees, and the only charge is on your own winning trades when it executes your strategy to your own broker account.
Per its published pages as of July 2026: a listing fee of 120 dollars per six months, plus a platform share of subscription revenue that its own materials have quoted between 30 and 50 percent depending on strategy type. Verify current terms directly with Collective2 before listing.
Yes. Nothing in Sonar Sciences prevents listing elsewhere; check Collective2's current exclusivity terms on their side. The validated, versioned record is built on Sonar Sciences, and distribution stays wherever your audience already is.
Bring one strategy you already trust. The Studio validates it against four years of real data, costs included, for free.
Start building